This product has switched from a hybridoma to recombinant production method on 8th March 2021.
 This product is a recombinant monoclonal antibody, which offers several advantages including:
  - - High batch-to-batch consistency and reproducibility
  - - Improved sensitivity and specificity
  - - Long-term security of supply
  - - Animal-free production